How Does the COVID-19 Pandemic Influence Histopathological Outcomes for Urologic Cancers?

Abstract

Objective: The coronavirus disease 2019 pandemic disrupted all routine health care services and resulted in a significant reconfiguration of urologic cancer services and care pathways across the globe. This study aimed to retrospectively determine the pandemic's impact on the urologic oncological surgery outcomes at a high-volume referral center.Materials and methods: We compared the number and histopathological outcomes of urologic oncological procedures in a referral center coded during the pandemic and data of the period before the pandemic as control. Data were extracted from patient files and hospital records. The pathological examination included a complete histopathological staging according to TNM stage.Results: A total of 683 patients were included in the study, 424 (62%) of which were operated in the prepandemic period. There was a 39% decline in urologic oncological surgical activity in the pandemic, mostly in renal and prostate cancer. The mean tumor size was larger in renal cancer patients who underwent surgery during the pandemic (5.6 cm vs 4.5 cm, p=0.002). During the pandemic, more lymph node involvement was seen after radical cystectomy and prostatectomy (50% vs 27.8%, p=0.024 and 12.5% vs 4.5%, p=0.026, respectively). No differences in terms of main pathologic features were observed in patients undergoing radical orchiectomy.Conclusion: COVID-19 appeared to adversely effect oncologic outcomes in patiens undergone surgery for prostate and bladder cancer. Tumor development induced by a delay in diagnosis may cause severe consequences for patients. Reprioritizion of non-deferrable urologic oncological seems crucial.

Surgical oncology during the post‐COVID‐19 era: What is next?

“…Moreover, a 39% decline in urologic oncological surgical activity was observed during the pandemic, especially in renal and prostate cancer. The mean tumor size was larger in renal cancer patients who underwent surgery during the pandemic (5.6 vs. 4.5 cm, p = 0.002) and more extended lymph node involvement was reported after radical cystectomy and prostatectomy (50% vs. 27.8%, p = 0.024 and 12.5% vs. 4.5%, p = 0.026, respectively) 15 . In addition, a large retrospective population‐based cohort study in Canada highlighted that neoadjuvant treatment for breast cancer was more common in the COVID‐19 era than the pre‐COVID‐19 era (47.9% vs. 27.2%, p < 0.001).…”

“…The mean tumor size was larger in renal cancer patients who underwent surgery during the pandemic (5.6 vs. 4.5 cm, p = 0.002) and more extended lymph node involvement was reported after radical cystectomy and prostatectomy (50% vs. 27.8%, p = 0.024 and 12.5% vs. 4.5%, p = 0.026, respectively). 15 In addition, a large retrospective population-based cohort study in Canada highlighted that neoadjuvant treatment for breast cancer was more common in the COVID-19 era than the pre-COVID-19 era (47.9% vs. 27.2%, p < 0.001). This trend was consistent across a range of systemic therapy regimens, but differed according to patient age and geography.…”